Pharmaceuticals company Caplin Point Laboratories announced Q2FY26 results Revenue from Operation: Rs 534.0 crore compared to Rs 483.1 crore during Q2FY25, change 10.5%. EBITDA: Rs 219.5 crore compared to Rs 185.5 crore during Q2FY25, change 18.3%. EBITDA Margin: 38.9% for Q2FY26. PBT: Rs 201.0 crore compared to Rs 168.5 crore during Q2FY25, change 19.3%. PAT: Rs 160.2 crore compared to Rs 130.8 crore during Q2FY25, change 22.5%. C.C. Paarthipan, Chairman, said: "Consistency has been the cornerstone of Caplin’s journey. We are pleased to report another strong set of results, fully aligned with our long-term growth path and guidance. Our unwavering focus on cashflows, profitability, and revenue growth continues across all segments of the business, complemented by an equally strong commitment to compliance and governance. We are leveraging our deep understanding of smaller Latin American markets through our subsidiaries in the front end, together with our R&D; and supply chain excellence at the back end, to create a powerful foundation for expansion into larger markets such as Mexico, Chile, Colombia, and eventually Brazil. Our relentless emphasis on compliance and operational productivity continues to drive robust growth in regulated markets like the U.S. and Canada, and we expect this segment to represent an even greater share of our business in the coming years. Meanwhile, our China 2.0 strategy positions us to fast-track entry into high-potential areas such as Biosimilars and Peptides — segments traditionally dominated by larger players. The building blocks we are putting in place from now and over the next couple of year will set Caplin on a strong, multi-year growth trajectory, underpinned by the same consistency, discipline, and performance metrics that have defined us thus far." Result PDF
